Department of Hepatic-Biliary-Pancreatic Surgery, The 371971First People's Hospital of Neijiang, Neijiang, Sichuan, China.
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211004915. doi: 10.1177/15330338211004915.
The mortality and recurrence of patients with cancer is of high prevalence. SET-binding factor 2 (SBF2) antisense RNA1 (lncRNA-SBF2-AS1) is a promising long non-coding RNA. There is increasing evidence that SBF2-AS1 is abnormally expressed in various tumors and is associated with cancer prognosis. However, the identification of the effect of lncRNA SBF2-AS1 in tumors remains necessary.
Up to November 2, 2020, electronic databases, including PubMed, Cochrane Library, EMBASE, Medline, and Web of Science, were searched. The results were evaluated by pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs).
A total of 11 literatures on cancer patients were included for the present meta-analysis. The combined results revealed that high expression of SBF2-AS1 was significantly associated with unfavorable overall survival (OS) (HR = 1.48, 95% CI: 1.34-1.62, < 0.00001) in a variety of cancers. In additional, the increase in SBF2-AS1 expression was also correlated with tumor size ((larger . smaller) OR = 2.34, 95% CI: 1.47-3.70, = 0.0003), advanced TNM stage ((III/IV . I/II) OR = 2.78, 95% CI: 1.75-4.41, < 0.0001), lymph node metastasis ((Positive . Negative) OR = 3.06, 95% CI: 1.93-4.86, < 0.00001), and histological grade ((poorly . well/moderately) OR = 2.58, 95% CI: 1.47-4.52, = 0.001) in patients with cancer. Furthermore, The Cancer Genome Atlas (TCGA) dataset valuated that SBF2-AS1 was upregulated in a variety of tumors, and predicted the worse prognosis.
Our results of this meta-analysis demonstrate that high SBF2-AS1 expression may become a potential target for predicting the prognosis of human cancers.
癌症患者的死亡率和复发率普遍较高。SET 结合因子 2（SBF2）反义 RNA1（lncRNA-SBF2-AS1）是一种很有前途的长非编码 RNA。越来越多的证据表明，SBF2-AS1 在各种肿瘤中异常表达，并与癌症预后相关。然而，鉴定 lncRNA SBF2-AS1 在肿瘤中的作用仍然是必要的。
截至 2020 年 11 月 2 日，检索了包括 PubMed、Cochrane 图书馆、EMBASE、Medline 和 Web of Science 在内的电子数据库。通过合并优势比（ORs）和风险比（HRs）及其 95%置信区间（CIs）评估结果。
本荟萃分析共纳入 11 项癌症患者文献。综合结果表明，在多种癌症中，SBF2-AS1 高表达与不良总生存期（OS）显著相关（HR=1.48，95%CI：1.34-1.62，<0.00001）。此外，SBF2-AS1 表达的增加也与肿瘤大小（（较大. 较小）OR=2.34，95%CI：1.47-3.70，=0.0003）、晚期 TNM 分期（（III/IV. I/II）OR=2.78，95%CI：1.75-4.41，<0.0001）、淋巴结转移（（阳性. 阴性）OR=3.06，95%CI：1.93-4.86，<0.00001）和组织学分级（（差. 中/高）OR=2.58，95%CI：1.47-4.52，=0.001）有关。此外，癌症基因组图谱（TCGA）数据集评估表明，SBF2-AS1 在多种肿瘤中上调，并预测预后较差。
本荟萃分析结果表明，SBF2-AS1 高表达可能成为预测人类癌症预后的潜在靶点。
